Flower Pollen Extract and its Effect on Menopause - Graminex

<strong>Flower</strong> <strong>Pollen</strong> <strong>Extract</strong> <strong>and</strong> <strong>its</strong> <strong>Effect</strong> onMenopauseContentsFindings on Female Menopausal Disorders through the "<strong>Pollen</strong> <strong>Extract</strong> G63" of Graminex Company .......2Clear cell adenocarcinoma of the female urethra showing strong immunostaining for prostate‐specificantigen..........................................................................................................................................................41 | P a g e

Findings on Female Menopausal Disorders through the "<strong>Pollen</strong> <strong>Extract</strong>G63" of Graminex CompanyHiromi Yokoyama Naofumi Suzuki Yoshimi Nishimura(K<strong>and</strong>a New Medical Clinic)Female Menopausal Disorders occur at the onset of menopause, have as a characteristic ofindeterminate complaints, interference even occurs with intercourse, <strong>and</strong> becomes a source ofdiscord in partner relationships. A reduction of female hormones has been talked about as thecause. Here, we have examined the influence of pollen extract G63 on hormones <strong>and</strong>improvement of the associated indeterminate complaints.[Objective <strong>and</strong> Methods]Six females, four in menopause <strong>and</strong> two evidencing menopausal symptoms having menstrual periodevery 4~5 months, were studied for degree of improvement according to two hormones Estradiol <strong>and</strong>DHEAS <strong>and</strong> the consultation questionnaire. The period of the trial was from 1 to 3 months. The pollenextract used in the trial was produced by Graminex Company in Ohio, USA from the pollen of rawmaterials such as rye, corn, <strong>and</strong> timothy hay (referred to as Phleum pratense in Japan) which werecultivated without using agrochemicals or genetically modified varieties. The pollen which has a doublehull is not digested or absorbed even when ingested since it has strong resistance to acid <strong>and</strong> heat(cannot be destroyed even at 300°C). Graminex Company using a special technology is able toseparately extract G60 (water soluble nutrition components) <strong>and</strong> GFX (lipid soluble components) <strong>and</strong> wereceived the product G63 which is a 20:1 combination G60 <strong>and</strong> GFX.The dosage was 6 tablets per day; three tablets each taken after breakfast <strong>and</strong> dinner. One 250 mg tabletcontains 62.5 mg of pollen extract.(The daily quantity .... 375mg as pollen extract)Our own medical questionnaire was prepared <strong>and</strong> the number of points evaluated. (Lower points indicatemilder symptoms)No Symptoms None Slightly Medium HighPresent intensity intensity1 Heat sensitivity (burning 0 1 2 3sensation, hot flashes)2 Chilling, numbness, edema of 0 1 2 3h<strong>and</strong>s or feet3 Perspiration 0 1 2 34 Tachycardia (rapid heart 0 1 2 3beat)5 Palpitation 0 1 2 36 Chest pains <strong>and</strong> 0 1 2 3breathlessness7 Headaches 0 1 2 38 Feel heavy-headed 0 1 2 39 Insomnia 0 1 2 32 | P a g eFindings on Femaile Menopausal Disorders through the<strong>Pollen</strong> <strong>Extract</strong> G63 of Graminex Company

10 Depression 0 1 2 311 Irritability 0 1 2 312 Feeling of anxiety 0 1 2 313 Dizziness 0 1 2 314 Feel dizzy upon st<strong>and</strong>ing up 0 1 2 315 Tinnitus (ringing in ears) 0 1 2 316 Stiff shoulders 0 1 2 317 Arthralgia in h<strong>and</strong>s <strong>and</strong> feet 0 1 2 318 Lumbago 0 1 2 319 Numbness 0 1 2 320 Sensation like ants crawling 0 1 2 3on the skin[Results]Graminex <strong>Pollen</strong> Therapy Trials ... Female Menopausal DisorderName Age Examination Estradiol DHEAS ConsultationDayquestionnaireO_ T 48 Before Less than 10 65 17AdministrationLess than 10After 2 Less than 10 83 21monthsY_ T 53 Before Less than 10 72 13AdministrationAfter 1 month Less than 10 89 6S_ M 54 Before 14 142 3AdministrationAfter 1 month Less than 10 112 4F_ N 50 June 21, 2005 27 106 420 79 2N_ A 63 June 21, 2005 Less than 10 121 5Less than 10 123 2K_ H 48 June 22, 2005 24 65 15Less than 10 74 10[Conclusion] The increase in Estradiol was 0 for all subjects. DHEAS increased in 4 out of the 6 subjects<strong>and</strong> the average was 14.2%. Indeterminate complaints improved in 4 of the 6 subjects for a 54.1% degreeof improvement.[Discussion] It can be considered that the improvement observed in indeterminate complaints was dueto the amino acids, vitamins, <strong>and</strong> mineral components of the pollen extract which in the body assisted thepromotion of metabolism. Additionally, there is evidence of rejuvenation with secretion of DHEAS whichnormally peaks for persons in their twenties. Moreover, the DHEAS value is also used as an indicator offemale sexual desire <strong>and</strong> it can be considered that sexual appetite was also increased <strong>and</strong> it can beassumed that increased DHEAS helps to remove interference to intercourse for menopausal females.[Safety] Among the findings, in particular there were no side-effects <strong>and</strong> the supplement can beadministered with peace of mind.8/23/20053 | P a g eFindings on Femaile Menopausal Disorders through the<strong>Pollen</strong> <strong>Extract</strong> G63 of Graminex Company

Clear cell adenocarcinoma of the female urethra showing strongimmunostaining for prostate­specific antigenK. KAWANO, M. YANO, S. KITAHARA <strong>and</strong> K. YASUDADepartment of Urology, Dokkyo University School of Medicine, Koshigaya Hospital, Saitama, JapanCase reportA 49‐year‐old woman presented with the chiefcomplaint of voiding difficulty. On digital vaginalexamination, a walnut‐sized mass was con®rmedaround the urethra. Abdominal ultrasonographyshowed a mass at the bladder neck (Fig. 1), <strong>and</strong>cystoscopy revealed the tumour protruding from theposterior urethral wall at the bladder neck.Subsequent bone scintigraphy, systematic CT <strong>and</strong>serum chemistry showed no metastasis. The patientunderwent transurethral biopsy of the tumour, <strong>and</strong>the histological diagnosis was carcinoma composedof high‐grade cancer cells. Under the diagnosis of aninvasive but localized urethral tumour, totalcystourethrectomy was performed, includinganterior vaginal wall <strong>and</strong> pelvic lymph nodedissection. An ileal conduit was chosen for urinarydiversion. The anterior vaginal wall was intact, butthe tumour invaded the mucosa <strong>and</strong> muscle layer ofthe bladder trigone. No lymph node metastasis wasdetected. The patient was free of disease a year aftersurgery. Microscopy of the tumour showed clear‐celltype adenocarcinoma, most of which containedclearly vacuolated cytoplasm <strong>and</strong> pleomorphic nuclei(Fig. 2a). The histological diagnosis was mesonephricadenocarcinoma. Immunohistochemical staining,using the two‐step indirect immunoperoxidasetechnique with antibodies to PSA (L‐1838, Dako,Glostrup, Denmark), showed strong cytoplasmicreaction in the tumour cells (Fig. 2b). Serum PSAlevels were not measured before surgery, but at thefollow‐up serum PSA levels were estimated severaltimes (T<strong>and</strong>em‐R, Hybritech, San Diego, CA, USA); allwere below the detectable limit (

the female clear cell adenocarcinoma arises from thepara‐urethral duct, as the present case was alsopositive immunohistochemically for PSA. However,there are variable terms for the neoplasm, e.g.mesonephroma, adenocarcinoma of Skene's paraurethralgl<strong>and</strong>s, <strong>and</strong> tumour of theFig. 2. a, Sections of the tumour showing clear cell type adenocarcinoma (haematoxylin <strong>and</strong> eosin r400) <strong>and</strong> b, immunohistochemicalstaining for PSA showing a strong cytoplasmic reaction in the tumour (r600).female para‐urethral duct. Therefore, the use of amore unified nomenclature is desirable. Clear celladenocarcinoma of the female urethra is acomparatively rare entity; there are 42 cases of thisneoplasm reported, including the present case, fiveof which had positive immunohistochemical stainingfor PSA. Only one was negative, but microscopyshowed this tumour to be truly of para‐urethral ductorigin [5].CLEAR CELL ADENOCARCINOMA 413References1. Peven DR, Hidvegi DF. Clear‐cell adenocarcinoma of thefemale urethra. Acta Cytol 1985; 29: 142±62. <strong>Pollen</strong> JJ, Dreilinger A. Immunohistochemicalidenti®cation of prostatic acid phosphatase <strong>and</strong> prostatespeci®cantigen infemale periurethral gl<strong>and</strong>s. Urology 1984; 23: 303±43. Spencer JR, Broden AG, Ignatoff JM. Clear celladenocarcinoma of the urethra: evidence for origin withinparaurethral ducts. J Urol 1990; 143: 122±54. Zaviacic M, Sidlo J, Borovsky M. Prostate speci®c antigen<strong>and</strong> prostate speci®c acid phosphatase in adenocarcinomaof Skene's paraurethral gl<strong>and</strong>s <strong>and</strong> ducts. Virchows Arch APathol Anat Histopathol 1993; 423: 503±55. Kamoto T, Noguchi T, Okabe T, Takai I, Matsumoto M. Acase of clear cell adenocarcinoma of the female urethra.Acta Urol Jpn 1993; 39: 965±6AuthorsK. Kawano, MD, Urologist.M. Yano, MD, Urologist.S. Kitahara, MD, PhD, Associate Professor.K. Yasuda, MD, PhD, Professor.Correspondence: Department of Urology, DokkyoUniversity School of Medicine, Koshigaya Hospital, Saitama,Japan.# 2001 BJU International 87, 412±4135 | P a g eClear Cell Adenocarcinoma of the Femail Urethra showing StrongImmunostaining for prostate-specific antigen